GoodRx
GoodRx's revenue rose 0.6% to $797 million in fiscal 2025. Its operating margin was 11.0%, up from 8.3% a year earlier. Free cash flow was $164 million, down 10.0%. It paid out $216 million in dividends and buybacks, 132% of free cash flow. The diluted share count fell 9.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What GoodRx does
GoodRx runs apps and websites that show Americans what their prescription drugs cost at nearby pharmacies and give them discount codes to pay less. The prices are free to see and can be used at nearly every retail pharmacy in the United States, by people with or without insurance. It also offers paid subscriptions, Gold and RxSmartSaver+, with lower prices at some pharmacies, and telehealth visits through GoodRx Care.
Most of the discounted prices come from pharmacy benefit managers (PBMs), the companies that negotiate drug prices for insurers and employers. When a customer fills a prescription with a GoodRx code, the PBM pays GoodRx a share or a fixed fee, and it keeps paying on refills. In 2025, revenue from these prescription transactions fell $33.5 million, partly because Monthly Active Consumers dropped 14% amid pharmacy store closures. Pharma direct, which advertises drug makers' savings programs for brand-name medicines, grew 41%. Subscriptions are the third line.
GoodRx says it competes mainly with other prescription savings companies and with firms that serve drug makers. In February 2026 the government launched TrumpRx, a site offering drug makers' discounts directly to consumers, and GoodRx works with drug makers that list prices there. It had 697 employees at the end of 2025, all full time.
Its biggest risks, as it describes them
- A small number of PBMs supply many of the discounted prices it shows, so losing or changing those contracts would cut revenue.
- Much of its revenue comes from transactions at pharmacy chains, which are closing stores.
- Government drug pricing programs and new direct-to-consumer sites could change how people look for drug discounts.
- Failing to persuade people to use its platform when buying medicines, or to keep them coming back.
- A few large stockholders hold much of the voting power, which limits other shareholders' say.
Income statement
From fiscal 2018 to 2025, earnings per share fell 4.0% a year and net income 5.1% a year, as new shares raised the share count by 202% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 941 | 757 | 672 | 448 | 262 |
| Debt incl. finance leases | 674 | 667 | 656 | 500 | 495 |
| Net debt (negative means net cash) | −267 | −90 | −16 | 52 | 233 |
| Net debt to EBITDA | −5.6x | −1.6x | −0.2x | 0.4x | 1.4x |
| Debt to equity | 0.8x | 0.8x | 0.9x | 0.7x | 0.8x |
| Interest coverage | 0.6x | 0.1x | −0.5x | 1.2x | 2.0x |
| Current ratio | 13.4x | 12.1x | 7.1x | 5.3x | 2.6x |
| Quick ratio | 13.4x | 12.1x | 7.1x | 5.3x | 2.6x |
Cash flow
Projections
Project GoodRx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought GoodRx shares on the open market, and 2 insiders sold $9.7 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Francisco Partners Iv-A L.p.10% owner | Sold | 1,296,177 | $3.50 | $4.5 million | Form 4 |
| Aug 25, 2026 | Francisco Partners Iv-A L.p.10% owner | Sold | 127,273 | $3.44 | $437,819 | Form 4 |
| Aug 24, 2026 | Francisco Partners Iv-A L.p.10% owner | Sold | 143,594 | $3.46 | $496,835 | Form 4 |
| Aug 21, 2026 | Francisco Partners GP IV Management Ltd10% owner | Sold | 274,717 | $3.50 | $961,510 | Form 4 |
| Aug 20, 2026 | Francisco Partners GP IV Management Ltd10% owner | Sold | 447,259 | $3.52 | $1.6 million | Form 4 |
| Aug 19, 2026 | Francisco Partners GP IV Management Ltd10% owner | Sold | 471,975 | $3.53 | $1.7 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 8 | 7 of 8 | 6 of 8 |
| Rule of 40 | 16.2% | 28.7% | 21.2% |
| Altman Z'' | 0.96 | 0.61 | −0.18 |
| Accruals ratio | −9.2% | −11.2% | −9.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 5 of 8 | 7 of 8 | 6 of 8 |
Compare
Put GoodRx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| GoodRx | FY25 | 0.6% | 11.0% | 20.6% | 5.8% | 1.4x | 6 | |
| Claritev | FY25 | 3.7% | 3.0% | −1.3% | 0.5% | 9.7x | 5 | Compare |
| Doximity | FY26 | 13.1% | 33.3% | 50.6% | 91.3% | −3.3x | 4 | Compare |
| Hinge Health | FY25 | 50.6% | −92.9% | 29.0% | — | — | — | Compare |
| Waystar | FY25 | 16.5% | 22.7% | 25.8% | 3.5% | 3.6x | 5 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 250 | 388 | 551 | 745 | 767 | 750 | 792 | 797 |
| Revenue growth | — | 55.6% | 41.9% | 35.4% | 2.8% | −2.1% | 5.6% | 0.6% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 44 | 29 | 62 | 126 | 143 | 136 | 124 | 121 |
| Operating income | 77 | 140 | −276 | 13 | 2 | −27 | 66 | 88 |
| Net income | 44 | 66 | −294 | −25 | −33 | −9 | 16 | 30 |
| Diluted EPS (US$) | 0.12 | 0.18 | −1.07 | −0.06 | −0.08 | −0.02 | 0.04 | 0.09 |
| Diluted shares (millions) | 118 | 231 | 275 | 410 | 413 | 410 | 392 | 357 |
| Cash flow | ||||||||
| Cash from operations | 45 | 83 | 131 | 179 | 147 | 138 | 184 | 168 |
| Capital expenditure | 1 | 1 | 21 | 5 | 4 | 1 | 1 | 4 |
| Free cash flow | 44 | 82 | 111 | 174 | 143 | 137 | 183 | 164 |
| Dividends paid | 1,346 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 102 | 104 | 159 | 216 |
| Acquisitions | 0 | 31 | 56 | 140 | 157 | 0 | 0 | 43 |
| Stock-based compensation | 2 | 4 | 397 | 160 | 120 | 105 | 99 | 77 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 35 | 26 | 969 | 941 | 757 | 672 | 448 | 262 |
| Debt incl. finance leases | — | 671 | 681 | 674 | 667 | 656 | 500 | 495 |
| Total assets | — | 387 | 1,470 | 1,608 | 1,605 | 1,589 | 1,388 | 1,404 |
| Total liabilities | — | 737 | 759 | 776 | 790 | 827 | 663 | 788 |
| Shareholders' equity | −1,162 | −1,088 | 711 | 832 | 815 | 762 | 725 | 616 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 31.0% | 36.0% | −50.1% | 1.8% | 0.2% | −3.6% | 8.3% | 11.0% |
| Net margin | 17.6% | 17.0% | −53.3% | −3.4% | −4.3% | −1.2% | 2.1% | 3.8% |
| Free cash flow margin | 17.8% | 21.1% | 20.1% | 23.4% | 18.6% | 18.3% | 23.1% | 20.6% |
| Rule of 40 (growth + FCF margin) | — | 76.7% | 62.0% | 58.7% | 21.5% | 16.2% | 28.7% | 21.2% |
| Return on capital | — | — | — | 2.1% | 0.2% | −2.9% | 4.5% | 5.8% |
| Return on equity | — | — | — | −3.3% | −4.0% | −1.1% | 2.2% | 4.5% |
| Return on assets | — | — | −31.6% | −1.6% | −2.0% | −0.6% | 1.1% | 2.2% |
| Net debt to EBITDA | — | 4.2x | — | −5.6x | −1.6x | −0.2x | 0.4x | 1.4x |